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Background: The S977F mutation (c.2930CNT) in the CFTR gene (CFTR/ABCC7) is extremely rare. We describe the case of an adult patient
carrying the complex allele S977F/T5TG12 in trans with the F508del mutation. Mild respiratory manifestations arose in adulthood associated with
azoospermia, acute pancreatitis, minor hemoptysis and Cl− levels ranging from 40 to 42 mEq/L.
Method: Diagnosis was conﬁrmed by repeated NPD measurements, genetic DHPLC analysis and a recently described functional assay measuring
cAMP-dependent cell depolarization in peripheral blood monocytes.
Results: NPD measurements, DHPLC and monocyte functional assay (CF index=−18). Results were consistent with a CF phenotype.
Conclusions: The combined application of DHPLC and NPD analysis in the algorithm for CF diagnosis appears useful for the management of
similar cases. In addition, the novel monocyte functional assay might contribute to improve our diagnostic capability, counseling and better
treatment of these challenging clinical cases.
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with an incidence of about 1 in 3000 among Caucasians, and
mutations in the CFTR gene as basic defect. The clinical
manifestations of CF are extremely varied. To the present day,
more than 1900 mutations have been identified in the CFTR
gene. Most of them are somewhat rare, making CF diagnosis
by genotyping very difficult. Typical CF manifestations
include sweat chloride concentrations above 60 mmol/L,
sino-pulmonary disease, specific gastrointestinal and/or nutri-
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;ean Ccaused by congenital bilateral absence of vas deferens
(CBAVD). CF is typically associated with exocrine pancreatic
insufficiency, gradual loss of pulmonary function and lung
tissue destruction, and less frequently with sufficient residual
pancreatic function and a milder clinical picture [1]. A range of
even milder conditions caused by CFTR dysfunction are
known as CFTR related disorders [2], and they are associated
with limited deterioration over time and clinical manifestations
in at least one organ in the presence of normal or borderline
sweat chloride values. The lower limit of the borderline range
varies between 30 and 40 mmol/L according to age and
international guidelines [3,4].
In these subjects diagnosis must be confirmed through
additional testing including the search for rare CFTR mutations
and in vivo evaluation of the CFTR function byNPDmeasurement.ystic Fibrosis Society.
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to NPD, may also be used [3]. Most of these patients have exocrine
pancreatic sufficiency.
Diagnosis of non classical CF [3] is challenging. This is due
not only to the variety of manifestations that are the results of
the combination of the functional consequences of different
classes of CFTR gene mutations together with the effect of the
genetic background, including non-CF modifier genes, and of
the environmental factors [5].
In the summer of 2007 a 43 year-old male contacted our
Center for diagnostic definition, following sweat testing, with
chloride levels ranging from 38 to 44 mEq/L and a CT scan
showing bilateral bronchiectasis. Other clinical manifestations
included azoospermia, acute pancreatitis and minor hemopty-
sis, allergic bronchopulmonary aspergillosis and chronic lung
infection by Pseudomonas aeruginosa and Staphylococcus
aureus. Lung function was normal.
Sweat testing was carried out twice at our Center, according to
the Gibson and Cooke method (Sweat testing: Sample Collection
and Quantitative Analysis — Approved Guideline — Second
Edition — The National Committee for Clinical Laboratory
Standards (NCCLS)— document C34 A2 [ISBN-56238-407-4];
USA; 2000). The resulting chloride levels were 40 and 42 mEq/L.
An initial analysis was carried on with the aim of finding any of
the CFTR mutations that occur most frequently in the population
of the regions of northeast Italy, and for large deletions in the
CFTR gene, including CFTRdele17a-18 (3120+1kbdel8.6kb) and
CFTRdele1 (c4_IVS1+69del119bpins299bp). Reverse dot blot
(kits provided by InnoLipa, Innogenetics, Belgium) was used.
Following the detection of the F508del mutation, D-HPLC and
sequencingwere performed and results showed the presence of the
IVS8-(TG)mTn polymorphic alleles (TG)12T5/(TG)10T9, and of
the S977F mutation. It was not possible to test the parents since
they live in another region but three sisters were genotyped: one
had S977F, IVS8-Tn: T5/T7; one nomutations/variants, IVS8-Tn:
T7/T7; the other had F508del, IVS8-Tn: T9/T7. From this we
concluded that S977F was in cis with the polymorphic allele T5.
In the transmembrane domain 9 the residue 977F is highly
conserved among five species [6]. In comparison with L977F,
which is more conservative and considered as a polymorphism
[6,7] or associated with increased susceptibility to pancreatic
ductular obstruction, the rare mutation S977F [8] is less
conservative. The presence of this mutation is associated with
possible effects on function and consequent clinical manifes-
tations. This prediction is consistent with the case reported in
the literature, where a subject carrying the S977F mutation, in
addition to a “severe” classic CF-causing mutation on the other
allele (CFTR genotype G542X/S977F), presented with clinical
evidence of CF [9]. This observation could well be applicable
to L997F too. L977F has been associated with CF and a
complex allele (R117L,L977F) has recently been described that
could account for the variable phenotype [10]. The presence of
R117L was excluded in our patient. The case we describe, the
S977F allele in cis with the polymorphic site TG12T5, allows
the possibility that decreased mRNA expression, associated
with the TG12T5 allele, participates together with the amino
acid replacement, to CFTR functional impairment. In the casedescribed by Férec et al. the IVS8-Tn genotype was not reported.
In the Clinical and Functional Translation of CFTR 2 (CFTR2)
worldwide CF database, S977F is reported in 9 patients with 6 of
them having F508del in trans. Variable expression or penetrance
of this mutation has been demonstrated by clinical and functional
analyses (http://www.genet.sickkids.on.ca/resource/nl/CFnewslet.
69.html). If compared with all CF patients these 9 patients were
older and developed pancreatic insufficiency and the presence of
P. aeruginosa in sputum less frequently. In this group of 9 patients
sweat test average values were borderline. Our communication
provides data about a single patient and we therefore consider this
report of complementary relevance with the worldwide database,
particularly for the diagnostic process when a single case is
investigated.
In previous works, doubts arising from detection of a rare
mutation with uncertain consequences on CFTR function [11]
on cis with the polymorphic allele IVS8-(TG)12T5 [12] have
been overcome by evaluation of NPD functional testing. With
the objective of arriving at a conclusive diagnosis in this case,
we carried out NPD measurement testing as previously
described [13]. Three reliable measurements for the patient
were consistent with a CF phenotype. Fig. 1 shows one
representative tracing: the Wilschanski index [14] was calcu-
lated as equal to 1.23 (non CF values are b0.8 in our Center).
Baseline NPD value was −21 mV; the responses to amiloride
were 13 mV, 2.8 mV following 0 Cl− and isoproterenol.
We also wondered whether a newly described approach that
utilizes peripheral blood monocytes and reports outcomes as an
index named “CF index” [15] and where subjects with value
scores below 0 are considered to be possible CF subjects, could
support the diagnosis in this case. For this patient we calculated
a CF index of −18, in keeping with the established diagnosis of
CF (Fig. 2). A healthy carrier (F508del mutation) with CF
index +22 is shown as reference.
It is worth underlining the fact that this report does not
demonstrate the ability of the S977F mutation to cause a CF
phenotype on its own but rather can be considered a mutation
of varying clinical consequence: subjects need to be homozy-
gous for this mutation in the absence of the T5TG12 genotype
to properly assess the disease-causing potential of this
mutation. Furthermore, where genetic variants arise, the
complete scanning of the gene is required since synergies in
different variants/polymorphisms can affect the CFTR func-
tion and lead to manifestation of the disease, as in the case of
R117H [16].
The diagnosis of controversial cases is challenging and
requires the use of sophisticated diagnostic tools [6–9,11,12,16]
and for this patient the diagnostic algorithm proposed for CF [3]
has been successfully applied. Reporting clinical and electro-
physiological information about rare mutations is important for
the CF community because it helps to improve diagnostic
procedures and to develop better approaches to genetic
counseling. Indeed the extensive sequencing being carried out,
although essential if diagnostic procedure is to improve, has
identified a large number of genetic variants of uncertain
functional significance thus limiting the practical application of
this valuable information. In these non-classical cases it is critical
Fig. 1. NPD measurements. The agents indicated at the bottom were added at the times (minutes) shown on the x axis. On the y axis PD are expressed in mV. Top:
non-CF subject; bottom: patient. The graph was obtained during measurements in the left nostril and is representative of both nostrils.
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complex alleles.
Research in this field is active [17] but validation is necessary
and is available only for NPD and ICM [18,19], both of them
representing rather invasive approaches. Although no standard-
ized technique is available we are currently testing the value of
leukocytes as a source of primary cells useful to evaluate CFTR
function. We have recently measured CFTR agonist-dependent
membrane depolarization in non-epithelial primary cells and in
peripheral blood monocytes [15] as a potential complementary
approach to the study of CFTR function. In the case described
here we confirmed a correlation between NPD tracings and cell
depolarization in monocytes. The role of CFTR in monocytes is
currently under investigation and it is hoped that the results will
bring new insights to the pathogenesis of CF and sanction a
rationale for proposing the use of leukocytes as a potential
support for CF diagnosis.
The combined application of DHPLC and NPD analysis in the
algorithm for CF diagnosis appears useful for the management ofsimilar cases. In addition, the development and validation of
novel functional assays are expected to improve our diagnostic
capability and lead to improved counseling and better treatment
of these challenging clinical cases, including the use of
CFTR-targeted treatments now in sight.
Acknowledgment
We acknowledge the contribution of Emily Pintani and Laura
Menin for collaboration in data analysis and NPDmeasurements,
respectively.
J.J. and C.A. are Italian CF Research Foundation contract
holders.
This work has been supported by research grants issued by the
Lega Italiana Fibrosi Cistica (Italian Cystic Fibrosis League)
through Veneto Branch— Associazione Veneta Lotta contro la
Fibrosi Cistica Onlus and by the Italian Cystic Fibrosis Research
Foundation (Grants: FFC #5/2009, project adopted by the Rotary
Club of Trentino Nord e Tomasi Gioielli; Trentino Branch —
Fig. 2. Monocyte depolarization assay. Single cell fluorescence analysis was performed using DiSBAC2(3) as probe as previously described [15]. Measurements in
monocytes were performed in basal conditions (B) and in the presence of stimulus (S) added after 5 min (arrow). Exogenous induction of depolarization was utilized
as an internal positive control in monocytes at the end of measurement and in the presence of stimulus (data not shown). The CF index for a healthy carrier (F508del
mutation) was calculated to be +22 (top) while the CF index of monocytes derived from the patient was −18 (bottom).
824 C. Sorio et al. / Journal of Cystic Fibrosis 12 (2013) 821–825Associazione Trentina FC Onlus — in memory of “Anita
Furlini”; FFC #6/2010, project adopted by Delegazione FFC di
Verbania-Cusio_Ossola, Trentino Branch — Associazione
Trentina FC Onlus through the Gruppo di Sostegno FFC
Trentino in memory of Silvia Sommavilla, Consorzio Promotre
s.c.r.l., Antonio Guadagnin and Sons, Alessandra Boccanera;
FFC #26/2011, project adopted by Donatori SMS Solidale 2011,
Delegazione FFC di Varese, Associazione Trentina FC onlus).References
[1] Classification of cystic fibrosis and related disorders. J Cyst Fibros
2002;1:5–8.
[2] Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E,
et al. Recommendations for the classification of diseases as CFTR-related
disorders. J Cyst Fibros 2011;10(Suppl. 2):S86–S102.
[3] De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge
J, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax
2006;61:627–35.
[4] Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting
GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through
older adults: Cystic Fibrosis Foundation consensus report. J Pediatr
2008;153(2):S4–S14.[5] Cutting GR. Modifier genes in Mendelian disorders: the example of cystic
fibrosis. Ann N Y Acad Sci 2010;1214:57–69.
[6] Fanen P, Ghanem N, Vidaud M, Besmond C, Martin J, Costes B, et al.
Molecular characterization of cystic fibrosis: 16 novel mutations identified
by analysis of the whole cystic fibrosis conductance transmembrane
regulator (CFTR) coding regions and splice site junctions. Genomics
1992;13:770–6.
[7] Derichs N, Schuster A, Grund I, Ernsting A, Stolpe C, Kortge-Jung S,
et al. Homozygosity for L997F in a child with normal clinical and chloride
secretory phenotype provides evidence that this cystic fibrosis transmem-
brane conductance regulator mutation does not cause cystic fibrosis. Clin
Genet 2005;67:529–31.
[8] Salvatore F, Scudiero O, Castaldo G. Genotype–phenotype correlation in
cystic fibrosis: the role of modifier genes. Am JMedGenet 2002;111:88–95.
[9] Ferec C, Giroux MA, Audrezet MP, Robaszkiewicz M. TP53 and
oesophageal cancer. Pathol Biol (Paris) 1997;45:871–5.
[10] Lucarelli M, Narzi L, Pierandrei S, Bruno SM, Stamato A, d'Avanzo M,
et al. A new complex allele of the CFTR gene partially explains the
variable phenotype of the L997F mutation. Genet Med 2010;12:
548–55.
[11] Modiano G, Bombieri C, Ciminelli BM, Belpinati F, Giorgi S, Georges M,
et al. A large-scale study of the random variability of a coding sequence: a
study on the CFTR gene. Eur J Hum Genet 2005;13:184–92.
[12] Sosnay PR, Castellani C, Corey M, Dorfman R, Zielenski J, Karchin R,
et al. Evaluation of the disease liability of CFTR variants. Methods Mol
Biol 2011;742:355–72.
825C. Sorio et al. / Journal of Cystic Fibrosis 12 (2013) 821–825[13] Spinelli E, Seia M, Melotti P, Marchina E, Padoan R. CFTR mutation in an
Arab patient: clinical and functional features of 875+1G→A/875+1G→A
genotype. J Cyst Fibros 2009;8:282–4.
[14] Wilschanski M, Famini H, Strauss-Liviatan N, Rivlin J, Blau H, Bibi H,
et al. Nasal potential difference measurements in patients with atypical
cystic fibrosis. Eur Respir J 2001;17:1208–15.
[15] Sorio C, Buffelli M, Angiari C, Ettorre M, Johansson J, Vezzalini M, et al.
Defective CFTR expression and function are detectable in blood monocytes:
development of a new blood test for cystic fibrosis. PLoS One 2011;6:
e22212.
[16] Groman JD, Hefferon TW, Casals T, Bassas L, Estivill X, Des Georges M,
et al. Variation in a repeat sequence determines whether a common variant
of the cystic fibrosis transmembrane conductance regulator gene is
pathogenic or benign. Am J Hum Genet 2004;74:176–9.[17] Stumpf A, Almaca J, Kunzelmann K, Wenners-Epping K, Huber SM,
Haberle J, et al. IADS, a decomposition product of DIDS activates a cation
conductance in Xenopus oocytes and human erythrocytes: new compound
for the diagnosis of cystic fibrosis. Cell Physiol Biochem 2006;18:243–52.
[18] Bronsveld I, Sinaasappel M, Southern KW, Sermet-Gaudelus I, Leal T,
Melotti P, et al. Evaluation of European protocols for measuring nasal
potential differences. In: Doring G, editor. 32nd European Cystic Fibrosis
Conference; 2009. p. S10 [Brest].
[19] Derichs N, Sanz J, Von Kanel T, Stolpe C, Zapf A, Tummler B, et al.
Intestinal current measurement for diagnostic classification of patients
with questionable cystic fibrosis: validation and reference data. Thorax
2010;65:594–9.
